Evidence map›Paper›PMID 41233835›Full record

ArticleExperimental hematology & oncology2025

Targeting platelet-tumor cell interactions via thromboxane A

Veeresh Toragall, Ann C Rester, Salma Begum, Oluwaseyi T Shofolawe-Bakare, Kenneth Hulugalla, Jerry D Monroe, John P Bentley, Yann Gibert, Thomas A Werfel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental hematology & oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Veeresh ToragallDepartment of Biomedical Engineering, University of Mississippi, University, MS, 38677, USA.
Ann C ResterDepartment of Biomedical Engineering, University of Mississippi, University, MS, 38677, USA.
Salma BegumDepartment of Cell and Molecular Biology, Cancer Center and Research Institute, University of Mississippi Medical Center, Jackson, MS, 39216, USA.
Oluwaseyi T Shofolawe-BakareDepartment of Chemical Engineering, University of Mississippi, University, MS, 38677, USA.
Kenneth HulugallaDepartment of Biomedical Engineering, University of Mississippi, University, MS, 38677, USA.
Jerry D MonroeDepartment of Cell and Molecular Biology, Cancer Center and Research Institute, University of Mississippi Medical Center, Jackson, MS, 39216, USA.
John P BentleyDepartment of Pharmacy Administration, University of Mississippi, University, MS, 38677, USA.
Yann GibertDepartment of Cell and Molecular Biology, Cancer Center and Research Institute, University of Mississippi Medical Center, Jackson, MS, 39216, USA. ygibert@iu.edu.
Thomas A WerfelDepartment of Biomedical Engineering, University of Mississippi, University, MS, 38677, USA. tawerfel@olemiss.edu.

Funding

Training and Mentoring Core P20GM103476 · NIGMS · UNIVERSITY OF SOUTHERN MISSISSIPPI · PI Yufeng Zheng · 2012 to 2026
$60.2M
Role of obesity in preeclamptic pregnancy.P20GM121334 · NIGMS · UNIVERSITY OF MISSISSIPPI MED CTR · PI Jane F Reckelhoff · 2017 to 2026
$26.4M
The role of leptin in autoimmune-associated hypertensionP20GM104357 · NIGMS · UNIVERSITY OF MISSISSIPPI MED CTR · PI TAYLOR, ERIN BASSFORD · 2013 to 2022
$23.4M
American Cancer Society RSG-21-114-01-MMNIGMS NIH HHS P20 GM103476NIH HHS P20GM104357NIH HHS P20GM121334
6 · The paper itself

Abstract

In addition to their central role in blood hemostasis, it is increasingly clear that platelets contribute to multiple steps in the metastatic cascade. Platelets are one of the most abundant cells with which tumor cells interact once they enter the circulation, and the interaction of platelets with tumor cells can improve tumor cell survival, arrest and adhesion at secondary sites, and extravasation. Therefore, targeting the interaction between platelets and circulating tumor cells could be an effective approach for reducing metastasis. Here, we repurpose the thromboxane A

Indexed as

IfetrobanPlatelet activationThromboxane receptor and antimetastatic efficacy

Identifiers

PMID41233835
PMCPMC12613615

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.